Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenebrutinib vs Ocrelizumab in Primary Progressive Multiple Sclerosis
2022-502611-10-00Phase 3Authorised
- Sponsor
- Roche
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 30
01
Overview
Phase 3, randomised, double-blind trial of fenebrutinib in primary progressive multiple sclerosis (PPMS) (2 arms), sponsored by Roche. Primary endpoint: Time to onset of composite 12-week confirmed disability progression (cCDP12). Planned start Nov 2020; status: authorised.
02
Drugs
fenebrutinib
03
Conditions
primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on 2022-502611-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502611-10-00.